Promising new combo aims to wipe out leukemia cells more effectively
NCT ID NCT07228273
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the targeted drug venetoclax to a standard chemotherapy regimen (FLAG IDA) works better than the usual treatment for adults newly diagnosed with acute myeloid leukemia (AML). About 102 participants will receive either the new combination or standard care. The main goal is to see if the new combo leads to a deeper remission, where no cancer cells can be detected by sensitive tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax
What this could lead to
If successful, this could offer a more effective initial treatment for acute myeloid leukemia, potentially leading to deeper remissions and better long-term outcomes.
What could go wrong
This is a phase 2 trial with only 102 participants, so results are preliminary. The combination therapy may cause more side effects than standard care, and it is not yet known if it will improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact